富马酸丙酚替诺福韦治疗特殊慢性乙型肝炎的相关进展

Research advances in tenofovir alafenamide fumarate in treatment of special chronic hepatitis B

我国HBV感染人数众多,严重危害公共卫生安全。富马酸丙酚替诺福韦(TAF)作为临床一线用药,具有强效、低耐药、骨肾安全等特点。本文归纳总结了TAF在低病毒血症、多重耐药、妊娠期、肝衰竭及肝移植等特殊类型慢性乙型肝炎患者中的作用,分析表明TAF能够降低低病毒血症患者病毒载量实现病毒学应答、为耐药患者提供新方案、阻断母婴传播、降低终末期肝病患者病死率、改善慢性肾脏病患者肾功能。

There are a large number of individuals with HBV infection in China,which seriously endangers public health safety.As a first-line drug used in clinical practice,tenofovir alafenamide fumarate(TAF)has the characteristics of strong efficacy,low drug resistance,and bone and kidney safety.This article summarizes the role of TAF in patients with special types of chronic hepatitis B,such as low-level viremia,multidrug resistance,pregnancy,liver failure,and liver transplantation,and the analysis shows that TAF can reduce viral load in patients with low-level viremia to achieve virologic response,provide new regimens for patients with drug resistance,block mother-to-child transmission,reduce the mortality rate of patients with end-stage liver disease,and improve renal function in patients with chronic kidney disease.